BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided clinical development and operational highlights.
“ALX made substantial progress in 2020 towards advancing our lead development candidate, ALX148, marked by a growing body of positive data reported in solid tumors, including encouraging Phase 1b clinical data in combination with antibodies and standard chemotherapy in patients with gastric/gastroesophageal junction (“G/GEJ”) cancer and head and neck squamous cell carcinoma (“HNSCC”),” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology.
“In 2021, we are focused on reporting our Phase 1b full clinical results and initiating several clinical trials, including two randomized Phase 2 studies of ALX148 in combination with KEYTRUDA® (pembrolizumab) in patients with HNSCC, and the start of a Phase 1b clinical trial with ALX148 in combination with Zymeworks’ zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors in the first half of the year. In addition, randomized Phase 2 studies in myelodysplastic syndromes (“MDS”) and G/GEJ cancer will initiate in the second half of a very exciting year,” Dr. Pons continued.
Anticipated Key Clinical Milestones for 2021
Recent Clinical Developments for ALX148
Recent Operational Highlights:
Full Year and Fourth Quarter 2020 Financial Results:
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology’s website at www.alxoncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include, but are not limited to, statements regarding ALX Oncology’s financial condition, results of operations and sufficiency of its cash and cash equivalents to fund its planned operations as well as statements about ALX Oncology’s clinical pipeline, including the timing of clinical trial initiations and data releases, and the expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of ALX148. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Report on Form 10-K, filed with the SEC on March 18, 2021, and other documents ALX Oncology subsequently files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
ALX ONCOLOGY HOLDINGS INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended | Year Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Related-party revenue | $ | — | $ | 1,213 | $ | 1,182 | $ | 4,796 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 12,142 | 6,735 | 28,961 | 16,306 | ||||||||||||
General and administrative | 5,683 | 1,108 | 14,809 | 3,313 | ||||||||||||
Cost of services for related-party revenue | — | 1,103 | 1,075 | 4,360 | ||||||||||||
Total operating expenses | 17,825 | 8,946 | 44,845 | 23,979 | ||||||||||||
Loss from operations | (17,825 | ) | (7,733 | ) | (43,663 | ) | (19,183 | ) | ||||||||
Interest expense | (151 | ) | (21 | ) | (811 | ) | (21 | ) | ||||||||
Other expense, net | 5 | (1 | ) | (404 | ) | (5 | ) | |||||||||
Loss on early debt extinguishment | (621 | ) | — | (621 | ) | — | ||||||||||
Loss before income taxes | (18,592 | ) | (7,755 | ) | (45,499 | ) | (19,209 | ) | ||||||||
Income tax provision | (182 | ) | (9 | ) | (241 | ) | (34 | ) | ||||||||
Net loss and comprehensive loss | (18,774 | ) | (7,764 | ) | (45,740 | ) | (19,243 | ) | ||||||||
Cumulative dividends allocated to preferred stockholders | — | (1,071 | ) | (5,202 | ) | (4,028 | ) | |||||||||
Net loss attributable to common stockholders | $ | (18,774 | ) | $ | (8,835 | ) | $ | (50,942 | ) | $ | (23,271 | ) | ||||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.50 | ) | $ | (2.83 | ) | $ | (2.76 | ) | $ | (7.56 | ) | ||||
Weighted-average shares of common stock used to compute net loss per share attributable to common stockholders, basic and diluted | 37,642,897 | 3,122,204 | 18,485,343 | 3,076,461 | ||||||||||||
Condensed Consolidated Balance Sheet Data
(unaudited)
(in thousands)
December 31, 2020 | December 31, 2019 | ||||||
Cash and cash equivalents | $ | 434,219 | $ | 9,017 | |||
Total assets | $ | 436,054 | $ | 10,676 | |||
Total liabilities | $ | 6,209 | $ | 10,952 | |||
Convertible preferred stock | $ | — | $ | 70,363 | |||
Total stockholders’ equity (deficit) | $ | 429,845 | $ | (70,639 | ) |
GAAP to Non-GAAP Reconciliation
(unaudited)
(in thousands)
Three Months Ended | Year Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
GAAP net loss attributable to common stockholders, as reported | $ | (18,774 | ) | $ | (8,835 | ) | $ | (50,942 | ) | $ | (23,271 | ) | ||||
Adjustments: | ||||||||||||||||
Stock-based compensation expense | 1,743 | 75 | 5,436 | 297 | ||||||||||||
Accretion of term loan | 82 | 11 | 421 | 11 | ||||||||||||
Mark-to-market adjustment on financial instruments |
— | — | 650 | — | ||||||||||||
Loss on early debt extinguishment | 621 | — | 621 | — | ||||||||||||
Total adjustments | 2,446 | 86 | 7,128 | 308 | ||||||||||||
Non-GAAP net loss attributable to common stockholders | $ | (16,328 | ) | $ | (8,749 | ) | $ | (43,814 | ) | $ | (22,963 | ) |
Use of Non-GAAP Financial Measures
We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.
“Non-GAAP net loss attributable to common stockholders” is not based on any standardized methodology prescribed by GAAP and represent GAAP net loss adjusted to exclude (1) stock-based compensation expense, (2) accretion of term loan (interest expense related to ALX Oncology’s amortization of debt discount), (3) mark-to market adjustment on financial instruments (which include preferred stock warrants and derivatives) and (4) loss on early debt extinguishment within our reconciliation of our GAAP to Non-GAAP net loss. Non-GAAP financial measures used by ALX Oncology may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…
NEW YORK, July 1, 2024 /PRNewswire/ -- The global medical transcription market size is estimated to…
Toronto, Ontario--(Newsfile Corp. - July 1, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…
Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp. -…
SAN ANTONIO, July 1, 2024 /PRNewswire/ -- Replicare, a leading innovator in remote surgical telepresence…